ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Comparison of Efficacy and Safety of Tenofovir and Entecavir in Chronic Hepatitis B Virus Infection: A Systematic Review and Meta-Analysis

Ke Weixia; Liu Li; Zhang Chi; Ye Xiaohua; Gao Yanhui; Zhou Shudong; Yang Yi*广东药学院
PLoS ONE2014-6-6DOI: 10.1371/journal.pone.0098865
5阅读
引用收藏
分享

摘要

Objective: Tenofovir (TDF) and entecavir (ETV) are both potent antiviral agents for the treatment of chronic hepatitis B virus (HBV) infection. Multiple studies have compared efficacy and safety of these two agents, but yielded inconsistent results. Hence, we conducted a meta-analysis to discern comparative efficacy and safety. <br>Methods: Published data relevant to a comparison of TDF and ETV used in HBV were included. HBV DNA suppression rate, ALT normalization rate, and HBeAg seroconversion rate at 24 weeks and 48 weeks were reviewed. Drug safety profiles and resistance were also discussed. <br>Results: Seven articles met entry criteria. Four and six articles included data for 24 and 48-week HBV DNA suppression rates, respectively, and no significant differences for the rates between the two drugs were found in chronic HBV patients (TDF vs. ETV: relative risk [RR] = 1.10, 95% CI = 0.91-1.33 and RR = 1.07, 95% CI = 0.99-1.17 for 24 weeks and 48 weeks, respectively). For the ALT normalization rate (three studies for 24 weeks, four articles for 48 weeks) and HBeAg seroconversion rate (two and four studies for 24 weeks and 48 weeks, respectively), no difference was observed between TDF and ETV. Additionally, no significant distinction in short term safety was found for CHB patients. <br>Conclusions: TDF and ETV are similarly effective and safe in chronic HBV patients after 24 weeks and 48 weeks of anti-viral therapy. Nevertheless, the long-term efficacy and safety of TDF and ETV should be monitored in prolonged therapy.

相关
加载中…
  • 3-year Treatment of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate for Chronic HBV Infection in China
    Hou, Jinlin*; Ning, Qin*; Duan, Zhongping; Chen, You; Xie, Qing; Wang, Fu-Sheng; Zhang, Lunli; Wu, Shanming; Tang, Hong; Li, Jun; Lin, Feng; Yang, Yongfeng; Gong, Guozhong; Flaherty, John F.; Gaggar, Anuj; Mo, Shuyuan; Cheng, Cong; Camus, Gregory; Chen, Chengwei; Huang, Yan; Jia, Jidong; Zhang, MingxiangJournal of Clinical and Translational Hepatology, 2021, 9(3): 324-334.被引 17
  • Real-life impact of tenofovir disoproxil fumarate and entecavir therapy on lipid profile, glucose, and uric acid in chronic hepatitis B patients
    Zhang, Qi; Liang, Jinlin; Yin, Junhua; Jiang, Yiyue; Yu, Ning; Liao, Xingmei; Zhao, Siru; Wu, Leyuan; Fan, Rong*Journal of Medical Virology, 2022, 94(11): 5465-5474.被引 2
  • The Efficacy of Antiviral Treatment for Chronic Hepatitis B Patients with Normal ALT Levels: A Systematic Review and Meta-analysis
    Qian, Zhe; Hu, Meixin; Wu, Houji; Chen, Hongjie; Liao, Guichan; Kang, Zixin; Lin, Xiaoli; Peng, Jie*Hepatitis Monthly, 2022, 22(1): e129836.
查看全部 →

发表信息

论文状态
公开发表
期刊
PLoS ONE
发表日期
2014-06-06
卷期
第 9 卷, 第 6 期
页码
e98865
DOI
10.1371/journal.pone.0098865
语言
ENGLISH
期刊收录
SCIE
期刊等级
Q1
成果收录
SCI
资助标注
Program for Guangdong Medical research Foundation [B2012176]; National Natural Science Foundation of China [NSFC-81302493]; Foundation for Distinguished Young Talents in Higher Education of Guangdong [2012LYM_0082]

作者

  • K

    Ke Weixia (第一作者)

  • L

    Liu Li

查看全部 7 位作者收起作者
  • Z

    Zhang Chi

  • Y

    Ye Xiaohua

  • G

    Gao Yanhui

  • Z

    Zhou Shudong

  • Y

    Yang Yi (通讯)

    guangdong pharmaceut univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417